Article Text

Download PDFPDF

CE-28 Antimalarials protects against thrombosis in patients with systemic lupus erythematosus (SLE): longitudinal data from a large latin american cohort
  1. Guillermo J Pons-Estel1,
  2. Graciela S Alarcón2,
  3. Wojdyla Daniel3,
  4. Manuel F Ugarte-Gil4,
  5. Laurence S Magder5,
  6. Ana I Marcos6,
  7. Cristina Drenkard7,
  8. Alejandro J Alvarellos8,
  9. Eloisa Bonfa9,
  10. Lilian Lavras Costallat10,
  11. Loreto Massardo11,
  12. Antonio A Iglesias-Gamarra12,
  13. Marlene Guibert-Toledano13,
  14. Mary Carmen Amigo14,
  15. Mario H Cardiel15,
  16. Guillermo F Huerta-Yañez16,
  17. María H Esteva-Spinetti17 and
  18. Bernardo A Pons-Estel18
  1. 1Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain
  2. 2Department of Medicine, Division of Clinical Immunology and Rheumatology, School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA
  3. 3GLADEL consultant, Rosario, Argentina
  4. 4Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Perú
  5. 5University of Maryland Dental School, USA
  6. 6Hospital Interzonal General de Agudos “General San Martín”, La Plata, Argentina
  7. 7Division of Rheumatology, Emory School of Medicine, Atlanta, USA
  8. 8Servicio de Reumatología, Hospital Privado, Centro Medico de Córdoba, Córdoba, Argentina
  9. 9Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
  10. 10Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Brazil
  11. 11Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
  12. 12Universidad del Bosque, Bogotá, Colombia
  13. 13Centro de Investigaciones Médico Quirúrgicas- CIMEQ, Havana, Cuba
  14. 14Reumatología, Centro Medico ABC, Ciudad de México, Mexico
  15. 15Centro de Investigación Clínica de Morelia SC, Morelia, Michoacan, Mexico
  16. 16Hospital de Especialidades Miguel Hidalgo, Aguascalientes, Mexico
  17. 17Hospital Central de San Cristóbal, San Cristóbal, Venezuela
  18. 18Hospital Provincial de Rosario, Rosario, Argentina


Background Antimalarials (AMs) have shown to exert a thromboprotective effect in SLE patients, but studies thus far have been limited to North American and European patients. This study was conducted to assess whether a similar effect is observed in Latin American SLE patients.

Materials and methods SLE patients with a recent diagnosis (≤2 years) recruited and followed longitudinally as part of the GLADEL cohort were examined to establish risk factors for thrombotic events (TEs) and the possible preventive role of AMs. The end-point of this study was thrombosis defined as either arterial or venous occurring after entry into the cohort.

Independent variables included were socio-demographic characteristics, clinical manifestations as measured by the ACR classification criteria, laboratory, history of previous TEs and hospitalisation. For descriptive purposes, patients were divided according to use or non-use of an AMs agent (chloroquine and/or hydroxychloroquine) based on each patient’s entire follow-up period during the study. Patients were classified as “users” if they had received AMs for at least 6 months, whereas “non-users” comprised patients who had received AMs for less than 6 months or who had never received them.

Treatment with AMs, glucocorticoids and anticoagulants along with hospitalizations were considered as time-dependent covariates. The effect of AM use on thrombosis after adjustment for potential confounders (variables known to affect thrombosis and the use of AMs) was examined using a multivariable Cox regression model. A backward selection algorithm was used to select the variables retained in the model with α-level to stay in the model set to 0.05.

Results Of the 1,480 patients included in the GLADEL cohort, 1,208 (82%) were considered AMs users with median exposure time of 42.1 months (Q1–Q3: 19.1–62.3). TEs occurred in 103 (7%) of the patients during a median follow up time since enrolment of 15.4 months (Q1–Q3: 4.6–38.2). The rate of thrombosis for AM users was 1.44 per 100 patient/years of follow-up vs. 3.01 for non-AM users (HR 0.55, 95% CI: 0.37–0.82).

After adjusting for potential confounders in the Cox proportional hazards regression model, the use of AMs was associated with a 43% reduction in the thrombosis rate (HR 0.57, 95% CI: 0.38–0.85). Other variables significantly associated with TEs are depicted in Table 1.

Conclusions After adjusting for possible confounding factors related to AMs use, a clear protective effect of AMs in the development of TEs in SLE patients from this Latin American cohort was observed.

Acknowledgements On behalf of the Grupo Latino Americano De Estudio del Lupus (GLADEL) cohort.

Abstract CE-28 Table 1

Multivariable cox proportional hazard model: Time-to-thrombosis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.